Development and testing of the Satisfaction Questionnaire with Intravenous or Subcutaneous Hemophilia Injection and results from the Phase 3 HAVEN 3 study of emicizumab prophylaxis in persons with haemophilia A without FVIII inhibitors

INTRODUCTION: Emicizumab is a subcutaneously (SC) administered prophylactic agent for persons with haemophilia A (PwHA). As part of its clinical development, a new instrument was required to measure treatment satisfaction. AIM: Describe development of the Satisfaction Questionnaire with Intravenous...

Descripción completa

Detalles Bibliográficos
Autores principales: Kempton, Christine, Trask, Peter, Parnes, Aric, Niggli, Markus, Campinha‐Bacote, Avrita, U. Callaghan, Michael, O'Connell, Niamh, Paz‐Priel, Ido, Mahlangu, Johnny N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048849/
https://www.ncbi.nlm.nih.gov/pubmed/33506955
http://dx.doi.org/10.1111/hae.14222

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048849/
https://www.ncbi.nlm.nih.gov/pubmed/33506955
http://dx.doi.org/10.1111/hae.14222

Ejemplares similares